NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that specializes in developing gene silencing therapies utilizing synthetic antisense oligonucleotides. The company has established a platform known as Patrol, which is dedicated to creating treatments for rare genetic diseases, including Huntington's Disease, Myotonic Dystrophy, and Familial Parkinson's Disease. Through its innovative approach, NeuBase aims to address unmet medical needs in the field of genetic disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.